VHL disease-associated RCC, CNS haemangioblastomas, pNET
Oncology · 2024–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| belzutifan Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system… | Jul 2024 | Recommended with restriction | 516 individuals Medical Oncology Group · Rare Cancers Australia · Neuroendocrine Cancer Australia |
Who spoke
Medical Oncology Group · Rare Cancers Australia · Neuroendocrine Cancer Australia
What the PBS pays
$6M in government benefit over 2024–25, across 292 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| belzutifan | $6.5M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.